Delivery Order SPE2DB20D2014-SPE2DB25FC95F
- Not listed
- The Defense Logistics Agency (DLA) awarded a $10,158.47 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance scheduled for completion by July 29, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.92 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 27, 2025, with completion scheduled for August 28, 2025. This non-competitive, firm fixed-price delivery order represents a single procurement under AmerisourceBergen's larger contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, which serves as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Monovisc 88 mg/4 ml syringes with a ceiling value of $2,021.59. This is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a competitively awarded, non-set-aside contract. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply delivery. This...
- AmerisourceBergen Drug Corp was awarded a $3,443.09 delivery order by the Defense Logistics Agency (DLA) on August 15, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a non-set-aside, competitively awarded contract, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $9,013.11 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract is a firm fixed-price delivery order with a completion date of August 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for federal medical...
- The Defense Logistics Agency's Medical Supply Chain awarded a $14,790.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on August 22, 2025, with completion targeted for August 25, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the company's primary mechanism for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,229.88 on July 29, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitive award, with no set-aside designation, represents a firm fixed price contract with an ultimate completion date of July 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a $8,874.09 delivery order to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This contract employs firm fixed pricing and carries no set-aside designation, indicating it was awarded through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $41,326.09 delivery order by the Defense Logistics Agency on August 7, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This firm fixed-price contract, which is not a set-aside award, represents a competitive procurement executed under a larger indefinite delivery contract vehicle. The delivery order carries an ultimate completion date of August 8, 2025, with the...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC95FDelivery Order
The Defense Logistics Agency awarded a $9,521.32 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL units). This firm fixed-price contract, which must be completed by September 10, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively procured without set-aside restrictions, reflecting the contractor's established capability to meet federal pharmaceutical procurement requirements. Performance of this delivery order will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors, serves as a critical vendor for federal medical procurement through its comprehensive $999.99 billion IDC with DLA running through December 2026. The company supplies an extensive portfolio of pharmaceutical products and medical devices to support military healthcare systems globally, including medications, vaccines, syringes, and specialized medical commodities. This particular delivery order for Monovisc—a hyaluronic acid injection used for osteoarthritis treatment—exemplifies the company's role in fulfilling ongoing federal healthcare supply needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 9/9/25 |